Skip to content
Bored Studies
RecruitingPhase 2

A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Eli Lilly and Company · NCT07533019

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
66
US sites recruiting
18
Study start
April 14, 2026
Record last updated
October 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm).

Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

The study will last approximately 48 weeks, including screening.

Being studied: LY4005130; Placebo

Conditions: Vitiligo; Non-Segmental Vitiligo (NSV)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Eligible participants must have the following at both screening and baseline:
  • A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months
  • Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet
  • BSA involvement of ≥0.5% on the face
  • F-VASI ≥0.5 and T-VASI ≥3, and
  • Either active or stable disease at both screening and baseline

Exclusion Criteria

  • Participants who have other types of vitiligo that are not considered active or stable vitiligo
  • Currently have active forms of other disorders of pigmentation
  • Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment
  • Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved
  • Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening
  • Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data
  • Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve

Recruiting US locations

  • Medical Dermatology Specialists

    Phoenix, AZ 85006

    Site contact: 602-354-5770

  • Saguaro Dermatology - Phoenix

    Phoenix, AZ 85008

    Site contact: 480-562-3610

  • Center For Dermatology Clinical Research, Inc.

    Fremont, CA 94538

    Site contact: 510-797-0140

  • Northridge Clinical Trials

    Northridge, CA 91325

    Site contact: 818-350-7482

  • Cura Clinical Research - Oxnard

    Oxnard, CA 93030

    Site contact: 833-525-2872

  • Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway

    Santa Clarita, CA 91355

    Site contact: 833-525-2872

  • Health Clinical Research, LLC

    Miami, FL 33189

    Site contact: 786-280-1977

  • K2 Medical Research - Tampa

    Tampa, FL 33634

    Site contact: 813-800-5252

  • Advanced Medical Research, PC.

    Sandy Springs, GA 30328

    Site contact: Jamie Weisman

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, IN 46250

    Site contact: 317-516-5030

  • Brigham and Women's Hospital

    Boston, MA 02115

    Site contact: 617-732-4918

  • Revival Research Institute, LLC

    Troy, MI 48084

    Site contact: 248-590-0298

  • Stracskin

    Portsmouth, NH 03801

    Site contact: 617-833-9995

  • Equity Medical

    The Bronx, NY 10455

    Site contact: 332-223-6128

  • Accurate Clinical Research, Inc

    Humble, TX 77346

    Site contact: 281-760-3930

  • Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue

    San Antonio, TX 78235

    Site contact: 210-852-2779

  • Jordan Valley Dermatology & Research Center

    South Jordan, UT 84095

    Site contact: Douglass Forsha

  • Clinical Research Partners, LLC

    Richmond, VA 23226

    Site contact: 804-477-3045

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All dermatology studies in Arizona →
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo (NCT07533019) | Bored Studies